UK AI funding hits $9.6bn in H1 2026, up 360% year on year
UK artificial intelligence companies raised $9.6 billion in the first half of 2026, a 360% increase on the $2.1 billion recorded in the equivalent period of 2025, according to a semi-annual report published by data provider Tracxn. The surge was heavily concentrated: the top five funding rounds accounted for roughly 84% of the total capital deployed in the period.
The five largest recipients were Isomorphic Labs ($2.1bn Series B), Nscale ($2.0bn Series C), Wayve ($1.2bn Series D), Ineffable ($1.1bn Seed), and FluidStack ($843m Series A). All five are headquartered in London, which absorbed $9.4bn of the $9.6bn national total, leaving Oxford ($103m), Cambridge ($18m), and Edinburgh ($16m) as distant secondary markets.
Concentration and composition
The capital composition is notable for the weight of infrastructure plays. High-performance computing as a service and data-centre infrastructure together accounted for roughly $5.7bn of deployed capital, led by Nscale and FluidStack. Computational drug discovery, driven almost entirely by Isomorphic Labs, contributed $2.1bn. The pattern reflects a broader global dynamic in which foundational compute and model infrastructure attract the largest cheques, with application-layer companies competing for a smaller share of available capital.
Two new unicorns emerged in the period. Odyssey, a London-based developer of multimodal world-simulation models, reached the threshold following its $310m Series B in June 2026 at a reported $1.45bn valuation. Ineffable, which raised a $1.1bn seed round in April 2026, crossed the threshold at founding, an unusual outcome that reflects the scale of capital entering the market rather than a conventional progression through funding stages. Chemify, a Glasgow-based AI-driven chemistry platform, was added to Tracxn's Soonicorn list with a score of 59.1.
The report recorded 69 funding rounds in total during H1 2026, slightly down from 74 in H1 2025, indicating that the headline dollar figure reflects larger average round sizes rather than a broader increase in deal activity. The number of first-time funded companies fell 11% to 30, and new soonicorn additions dropped 33% to 16, consistent with a market in which capital is consolidating around established or high-profile names.
Market context and life sciences read-across
For biotech and life sciences technology companies, the Isomorphic Labs round is the most directly relevant datapoint. The company, which applies machine-learning methods to protein structure prediction and small-molecule drug discovery, raised its Series B from CapitalG, Temasek, and Google Ventures, among others. Computational drug discovery appeared as the second-largest funded business model in the period, suggesting sustained institutional appetite for AI-native approaches to target identification and molecular design.
The Tracxn data also flags Life Sciences Tech as the third-largest feed by funding at $2.1bn, though the report does not disaggregate this figure by sub-sector or named company. Readers seeking precision on which life sciences AI companies captured that capital will need to consult the underlying Tracxn platform data directly.
On the exit side, activity was muted. Six acquisitions were recorded and no IPOs completed in the UK during H1 2026. All acquisition prices were undisclosed. The absence of UK AI IPOs in the period contrasts with six in the US, pointing to continued preference among later-stage companies for remaining private or pursuing US listings, a structural issue that UK policymakers and investors have flagged repeatedly in recent years.
Internationally, the UK ranked third globally by AI funding at 3% of the worldwide total of $331bn, behind the US ($302bn, 91%) and ahead of China ($11.9bn) and Germany ($2.1bn).